The Progress In The Application Of Bevacizumab In Ovarian Cancer

Ovarian Cancer brings serious threat to the female normal life,only in the United States,each year about more than 20000 women were diagnosed with Ovarian Cancer,while killed about 10000 people,is the most deadly diseases in various malignant gynecological tumors.Because of atypical early clinical symptoms of ovarian cancer,most patient first clear diagnosis has been in the middle-late stage of the disease,tumor cells to destroy the loss and the application of chemical drugs,is has certain curative effect,but no significant role for common recurrent ovarian cancer metastasis,and most of the characteristics of the relapse of patients with chemotherapy drug resistance,make the follow-up treatment of the difficulties,the patient's quality of life and survival rate are in decline stage.Therefore,the current clinical tumor workers need to face the first priority,is appropriate for patients with ovarian cancer for new model of clinical intervention.Molecular Targeted therapy is a new type of biological methods for the treatment of malignant tumor,by changing the may target to promote the development of tumorigenesis,obstacles will lead to cancer sites,the reverse transformation from molecular level the malignant biological behavior of tumors,preventing tumor growth and metastasis.Bevacizumab(BV)is a type of monoclonal antibodies,by inhibition of VEGF by a functional effect,is a new type of targeted therapy drugs.In many countries abroad have been approved for the treatment of ovarian cancer.At home and abroad a large number of clinical trials showed that in the primary and recurrent ovarian cancer,bevacizumab is considered to be an extension of the ovarian cancer disease control period,raise the quality of survival is very promising drugs.While in use process will bring some side effects,but can be fully the use of management methods,and precaution and treatment toxicity reaction,which can effectively avoid gastrointestinal perforation of serious adverse events.In this paper,the mechanism of the role of bevacizumab in ovarian cancer,foreign main clinical trials and the results,common side effects and countermeasures,and curative effect of predictors of this a few aspects of research progress were reviewed,hope the clinical workers can more comprehensive understanding of this kind of targeted therapy drugs,provide more help for clinical work.